OCA
COGT icon

Octagon Capital Advisors’s Cogent Biosciences COGT Stock Holding History

Octagon Capital Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.9M Hold
2,350,000
– – 8.17% 4
2026
Q1 		$90.5M Hold
2,350,000
– – 10.01% 2
2025
Q4 		$83.5M Sell
2,350,000
-524,111
-18% -$14.7M 10.13% 3
2025
Q3 		$41.3M Buy
2,874,111
+111,111
+4% +$1.32M 6.26% 4
2025
Q2 		$19.8M Hold
2,763,000
– – 4.35% 10
2025
Q1 		$16.6M Hold
2,763,000
– – 3.2% 10
2024
Q4 		$21.6M Buy
2,763,000
+1,458,000
+112% +$14.5M 3.55% 8
2024
Q3 		$14.1M Buy
+1,305,000
New +$12.7M 2.19% 15

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Octagon Capital Advisors's COGT Position: Q2 2026 in Review

Octagon Capital Advisors held its Cogent Biosciences (COGT) position steady in Q2 2026 at 2,350,000 shares worth $90.9M. The position accounts for 8.17% of the portfolio, ranked #4.

Octagon Capital Advisors first reported a position in COGT in Q3 2024 and has held it in 8 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Octagon Capital Advisors held 2,350,000 shares of Cogent Biosciences worth $90.9M as of Q2 2026.
  • Octagon Capital Advisors left its Cogent Biosciences share count unchanged in Q2 2026.
  • Cogent Biosciences made up 8.17% of Octagon Capital Advisors's portfolio in Q2 2026, its #4 holding.
  • Octagon Capital Advisors first reported a position in Cogent Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.